Side-by-side comparison of AI visibility scores, market position, and capabilities
Kroger-owned in-store pharmacy chain with 2,200 locations in supermarket banners; prescription services integrated with grocery loyalty program competing with CVS and Walgreens.
Kroger Pharmacy is the pharmacy division of The Kroger Co., operating approximately 2,200 in-store pharmacies within Kroger supermarkets and Kroger-owned banner stores (Fred Meyer, King Soopers, Ralphs, Harris Teeter, Smith's, and others) across the United States — making it one of the largest pharmacy chains in the country. Part of Kroger (NYSE: KR), the nation's largest pure-play supermarket chain with approximately $150 billion in annual revenue, Kroger Pharmacy benefits from the combination of convenient supermarket co-location and Kroger's pharmaceutical purchasing scale.\n\nKroger Pharmacy provides prescription filling, immunization services, medication therapy management, and specialty pharmacy for complex medications. The pharmacy integrates with Kroger's loyalty program (Kroger Plus Card) to provide fuel points for pharmacy purchases and to connect prescription refill reminders with grocery shopping behavior. Kroger's OptUP nutrition scoring and health programs connect pharmacy and grocery to support customer health goals.\n\nIn 2025, Kroger Pharmacy competes with CVS Health, Walgreens, Walmart Pharmacy, and mail-order pharmacies for prescription market share. The retail pharmacy sector faces significant pressure from PBM reimbursement cuts and the shift to 90-day mail-order supply, which has forced pharmacy closures across the industry. Kroger's merger with Albertsons (blocked by FTC in February 2024) would have significantly expanded Kroger's pharmacy network, but the blocked merger leaves Kroger competing at current scale. The 2025 strategy focuses on integrating pharmacy into Kroger's digital health ecosystem, expanding specialty pharmacy capabilities, and leveraging Kroger Health data analytics for population health management programs.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.